Amphastar Pharmaceuticals, Inc. (AMPH)

Environment story

Amphastar discloses minimal environmental data. No formal Scope 1, 2, or 3 emissions inventories are published; no net-zero target year is stated. The company operates manufacturing facilities in China (Nanjing, 1.1M sq ft), France, and California, but carbon footprint and renewable energy percentages remain undisclosed. No evidence of significant resource controversies (toxic waste, water consumption disputes) appears in SEC filings. Manufacturing capacity expansion is planned but environmental impact assessments are not mentioned. Absence of disclosed ESG targets and climate commitments results in substantial deductions from the baseline score.

Social story

Amphastar provides limited disclosure of social metrics. CEO-to-median-worker pay ratio, workforce diversity percentages (gender, race/ethnicity in technical and executive roles), and turnover rates are not disclosed in the 10-K. Union standing information is absent; no evidence of union-suppression activities, NLRB complaints, or strikes within the past 24 months. The company acknowledges competition for talent, especially in Southern California, and notes prior executive attrition but does not quantify current workforce demographics. Supply-chain human-rights audits or conflict-mineral policies are not mentioned. Absence of formally disclosed diversity targets, DEI programs, and labor practices results in moderate deductions.

Governance story

Amphastar's governance structure is not fully disclosed in the 10-K. Board independence percentage, share class structure (single vs. dual-class), and lobbying expenditures are not explicitly stated. The 10-K confirms that the Audit Committee Chairperson has received a Cybersecurity Oversight certificate from Carnegie Mellon University and that cybersecurity oversight is assigned to the Audit Committee, with quarterly briefings to the board. No significant antitrust, consumer-safety, or financial-fraud regulatory proceedings are disclosed. The company faces substantial debt obligations (Wells Fargo Term Loan and 2029 Convertible Notes) with restrictive covenants limiting operational and acquisition flexibility. No evidence of shareholder activism lawsuits or climate-proposal litigation is present. Lack of transparent board-independence metrics and lobbying disclosure results in moderate deductions.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Amphastar Pharmaceuticals, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Amphastar Pharmaceuticals, Inc. in the app for interactive charts and portfolio building.

More in Healthcare